OncorMed offers genetic testing for inherited cancers:
This article was originally published in Clinica
Executive Summary
OncorMed has launched a test for mutations in the recently discovered BRCA2 breast and ovarian cancer gene. The company which is based in Gaithersburg, Maryland, is providing the new service in combination with its existing BRCA1 test. Approximately 185,000 patients will be diagnosed with breast cancer this year in the US. Between 5 and 10% of breast cancer is hereditary, with BRCA1 mutations accounting for about 45% and BRCA2 mutations accounting for about 35% of these cases.
You may also be interested in...
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
Diversified Sourcing And Sustainability Are Key For Centrient
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: